Inequalities in reperfusion therapy for STEMI
Key result
Omitting STEMI reperfusion is linked to ~3x higher 30-day mortality than primary PCI.
- n=7,917
Why the study?
Does reperfusion therapy reduce 30-day mortality in STEMI patients in Eastern Europe?
Population
7917 STEMI patients eligible for reperfusion therapy across 57 hospitals in Eastern Europe between 2010 and…
Comparison
Reperfusion therapy vs No reperfusion therapy
Design
Editorial
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Reperfusion gaps in Eastern European STEMI care demand urgent system-level fixes; leaves open prospective studies on implementation barriers.
Structured PICO
Does reperfusion therapy reduce 30-day mortality in STEMI patients in Eastern Europe?
P
Population
7,917 patients with STEMI eligible for reperfusion therapy across 57 hospitals in Eastern Europe between 2010 and 2015.
E
Exposure
Reperfusion therapy (intravenous fibrinolysis or primary percutaneous coronary intervention)
C
Comparator
No reperfusion therapy
O
Outcome
Mortality rates at 30 dayshard clinical
Despite clear guidelines, a significant proportion of STEMI patients in Eastern Europe do not receive reperfusion therapy, resulting in markedly higher 30-day mortality.
Cite This Study
Chris P Gale (2016) conducted an editorial in ST-elevation myocardial infarction (STEMI) (n=7,917). Reperfusion therapy (fibrinolysis or primary PCI) vs. No reperfusion therapy was evaluated on Mortality at 30 days. Among 7,917 STEMI patients in Eastern Europe, a quarter did not receive reperfusion therapy, resulting in 30-day mortality rates double those of fibrinolysis and treble those of primary PCI.